FDA Approves Bexlutry (lutetium Lu 177 dotatate) for Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors
NDA FilingapprovedBexlutryPositive
AI Analysis
Summary
The FDA approved Curium's Bexlutry (lutetium Lu 177 dotatate) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. This represents a significant regulatory achievement for the company's radiopharmaceutical therapy.
Outcome Details
FDA approved NDA for Bexlutry (lutetium Lu 177 dotatate) injection
Importance:8/10
Sentiment:
0.95
FDA ApprovalOncologyNeuroendocrine TumorsNuclear MedicineNDA Approval
Read the original article
Published by Drugs.com New Drug Approvals on September 14, 2026 2:09 AM